Intravenous Argatroban or Eptifibatide in Patients Undergoing Mechanical Thrombectomy

Does the addition of direct thrombin inhibitors or glycoprotein platelet inhibitors to intravenous thrombolysis in patients undergoing endovascular thrombectomy for acute ischemic stroke improve reperfusion rates and/or clinical outcomes?In this secondary analysis of the Multi-Arm Optimization of Stroke Thrombolysis (MOST) randomized clinical trial including 514 patients, the addition of argatroban and eptifibatide did not improve clinical outcomes nor the odds of achieving successful reperfusion.Future investigations of these agents as intravenous adjuncts to thrombectomy should focus on populations who are ineligible for intravenous thrombolysis.

Corresponding Author: Colin P. Derdeyn, MD, Department of Radiology and Medical Imaging, University of Virginia Medical Center, 1215 Lee St, Box 800170, Charlottesville, VA 22908 (cpd3yt@uvahealth.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.